Century Therapeutics Appoints New CMO, Director
Ticker: IPSC · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1850119
Sentiment: neutral
Topics: management-change, board-appointment, personnel
TL;DR
Century Therapeutics brings in a new CMO and a new board member, watch for strategic shifts.
AI Summary
Century Therapeutics, Inc. announced on September 26, 2024, the appointment of Dr. Lishan Chen as Chief Medical Officer and the election of Dr. David R. Boulware to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, though specific dollar amounts for these arrangements were not detailed in this filing.
Why It Matters
Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal shifts in company strategy, research direction, and future growth prospects.
Risk Assessment
Risk Level: medium — Appointments of key personnel and changes in board composition can impact strategic direction and operational execution, carrying inherent risks.
Key Players & Entities
- Century Therapeutics, Inc. (company) — Registrant
- Lishan Chen (person) — Appointed Chief Medical Officer
- David R. Boulware (person) — Elected to Board of Directors
- September 26, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Lishan Chen has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. David R. Boulware has been elected to the Board of Directors.
What is the exact date of this Form 8-K filing?
The exact date of this Form 8-K filing is September 26, 2024.
What is the principal executive office address for Century Therapeutics, Inc.?
The principal executive office address is 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104.
What is the SIC code for Century Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Century Therapeutics, Inc. is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 1,233 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2024-09-26 07:05:20
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select
- $470,000 — ntitled to (i) an annual base salary of $470,000 (ii) an annual performance-based target
- $100,000 — 2024, (iii) a one-time signing bonus of $100,000, (iv) an equity award consisting of (a)
Filing Documents
- tm2424946d1_8k.htm (8-K) — 33KB
- 0001104659-24-102988.txt ( ) — 206KB
- ipsc-20240926.xsd (EX-101.SCH) — 3KB
- ipsc-20240926_lab.xml (EX-101.LAB) — 33KB
- ipsc-20240926_pre.xml (EX-101.PRE) — 22KB
- tm2424946d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On September 26, 2024, the Century Therapeutics, Inc. (the "Company") announced the appointment of Morgan Conn, Ph.D. to serve as the Company's Chief Financial Officer, effective October 14, 2024 (the "Effective Date"). As of the Effective Date, Dr. Conn will serve as the Company's principal financial officer. Dr. Conn, age 56, previously served as the Chief Business Officer of Pharvaris N.V., since November 2017. Previously, Dr. Conn worked at PTC Therapeutics ("PTC") from 2001-2017, initially in research and subsequently helping to build the business development function, holding positions of increasing responsibility including Global Head and Vice President, Business Development. In 2017, Dr. Conn founded CallisBio, a consultancy offering strategic and implementation services in biopharma business and corporate development including transactions and financing. Early in his career, Dr. Conn served as an Assistant Professor in Chemistry at Amherst College, with a cross appointment in the Graduate Molecular and Cellular Biology program at the University of Massachusetts (Amherst). Dr. Conn holds a B.Sc. (Hons) in Chemistry and Biochemistry from the University of Toronto; a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology as both an NSF and NSERC pre-doctoral fellow; and, studied as a post-doctoral Research Fellow of the Miller Institute for Basic Research in Science at the University of California, Berkeley. In connection with Dr. Conn's appointment as the Company's Chief Financial Officer, the Company and Dr. Conn entered into an executive employment agreement on September 20, 2024 (the "Agreement"). Pursuant to the Agreement, which is effective as of the Effective Date, Dr. Conn is entitled to (i) an annual base salary of $470,000 (ii) an a
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: September 26, 2024